Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecapegfilgrastim for Dalpiciclib-Induced Neutropenia in Breast Cancer
NCT05463601Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Aug 2022
- Primary completion
- Jan 2025
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mecapegfilgrastim in neutropenia (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: The incidence of grade >=3 neutropenia at the end of cycle 1. Started Aug 2022; status: active, not recruiting.
02
Drugs
mecapegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT05463601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05463601.